TTD_Target_ID	Target_Name	TTD_Drug_ID	Drug_Name	Drug_Highest_Status	Drug_PubchemID	Molecular_Formula	Molecular_Weight	Canonical_SMILES	Activity	Binder_Type
T17569	Voltage-gated potassium channel Kv1.5	D03DAP	Flecainide	Approved	3356	C17H20F6N2O3	414.34	C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F	IC50 = 51000 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	B26CVM	4-Methoxy-N-(2,4,6-trimethylphenyl)benzenesulfonamide	Investigative	743974	C16H19NO3S	305.4	CC1=CC(=C(C(=C1)C)NS(=O)(=O)C2=CC=C(C=C2)OC)C	IC50 ~ 50118.72 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	B2ZOI6	N-[3-(N-(6-Fluoro-1,1-dioxo-1,2-benzothiazol-3-yl)anilino)-2,2-dimethylpropyl]-1-benzofuran-2-carboxamide	Investigative	52949881	C27H24FN3O4S	505.6	CC(C)(CNC(=O)C1=CC2=CC=CC=C2O1)CN(C3=CC=CC=C3)C4=NS(=O)(=O)C5=C4C=CC(=C5)F	IC50 ~ 50000 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	B4BN5I	Methyl 2-[(4-butoxyphenyl)sulfonylamino]-3-phenylpropanoate	Investigative	4998225	C20H25NO5S	391.5	CCCCOC1=CC=C(C=C1)S(=O)(=O)NC(CC2=CC=CC=C2)C(=O)OC	IC50 = 109740 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	B5E6XO	N-[3-(N-(6-Fluoro-1,1-dioxo-1,2-benzothiazol-3-yl)anilino)-2,2-dimethylpropyl]-1-methylpiperidine-4-carboxamide	Investigative	52946106	C25H31FN4O3S	486.6	CC(C)(CNC(=O)C1CCN(CC1)C)CN(C2=CC=CC=C2)C3=NS(=O)(=O)C4=C3C=CC(=C4)F	IC50 ~ 50000 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	B85ZDK	2-[4-[2-(3,4-Dimethylphenoxy)ethyl]piperazin-1-yl]-N-(1,3-thiazol-2-yl)acetamide	Investigative	90643648	C19H26N4O2S	374.5	CC1=C(C=C(C=C1)OCCN2CCN(CC2)CC(=O)NC3=NC=CS3)C	IC50 = 50240 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	BAJ3M7	1-[[3-(N-(6-Fluoro-1,1-dioxo-1,2-benzothiazol-3-yl)anilino)-2,2-dimethylpropyl]carbamoyl]cyclopropane-1-carboxylic acid	Investigative	52948768	C23H24FN3O5S	473.5	CC(C)(CNC(=O)C1(CC1)C(=O)O)CN(C2=CC=CC=C2)C3=NS(=O)(=O)C4=C3C=CC(=C4)F	IC50 ~ 50000 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	BAS95M	2-[(4-Butoxyphenyl)sulfonylamino]-3-(1H-indol-3-yl)propanoic acid	Investigative	72205888	C21H24N2O5S	416.5	CCCCOC1=CC=C(C=C1)S(=O)(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)O	IC50 = 65420 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	BEI5Y6	2-Morpholino-1,1-di(pyridin-3-yl)propan-1-ol	Investigative	11688027	C17H21N3O2	299.37	CC(C(C1=CN=CC=C1)(C2=CN=CC=C2)O)N3CCOCC3	IC50 ~ 60000 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	BEMB31	N-[3-(N-(6-Fluoro-1,1-dioxo-1,2-benzothiazol-3-yl)anilino)-2,2-dimethylpropyl]-3-hydroxypyridine-4-carboxamide	Investigative	52946322	C24H23FN4O4S	482.5	CC(C)(CNC(=O)C1=C(C=NC=C1)O)CN(C2=CC=CC=C2)C3=NS(=O)(=O)C4=C3C=CC(=C4)F	IC50 ~ 50000 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	BI6KA8	6-[({1-[2-(7-Methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one	Investigative	15982534	C24H28N6O4	464.5	COC1=CC2=C(C=C1)N=CC(=O)N2CCN3CCC(CC3)NCC4=NC5=C(C=C4)OCC(=O)N5	IC50 ~ 100000 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	BIP47M	2-[4-[2-(4-Tert-butylphenoxy)ethyl]piperazin-1-yl]-N-(1,3-thiazol-2-yl)acetamide	Investigative	90643650	C21H30N4O2S	402.6	CC(C)(C)C1=CC=C(C=C1)OCCN2CCN(CC2)CC(=O)NC3=NC=CS3	IC50 = 63180 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	BMWG84	6H-Pyrimido[5,4-b][1,4]oxazin-7(8H)-one, 2-[[[trans-4-[(1R)-1-amino-2-(7-fluoro-2-oxo-1(2H)-quinoxalinyl)ethyl]cyclohexyl]amino]methyl]-	Investigative	46206000	C23H26FN7O3	467.5	C1CC(CCC1[C@H](CN2C3=C(C=CC(=C3)F)N=CC2=O)N)NCC4=NC=C5C(=N4)NC(=O)CO5	IC50 ~ 100000 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	BN1J3L	2-[3-[2-[(4-Butoxyphenyl)sulfonylamino]ethyl]indol-1-yl]-N-(4-chlorophenyl)acetamide	Investigative	72205680	C28H30ClN3O4S	540.1	CCCCOC1=CC=C(C=C1)S(=O)(=O)NCCC2=CN(C3=CC=CC=C32)CC(=O)NC4=CC=C(C=C4)Cl	IC50 = 185140 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	BQD37A	(2-Chlorophenyl)-[4-(2-phenoxyethyl)piperazin-1-yl]methanone	Investigative	90643641	C19H21ClN2O2	344.8	C1CN(CCN1CCOC2=CC=CC=C2)C(=O)C3=CC=CC=C3Cl	IC50 = 56750 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	BR8HA0	2-Morpholin-4-yl-2-phenylethanol	Investigative	10899797	C12H17NO2	207.27	C1COCCN1C(CO)C2=CC=CC=C2	IC50 ~ 60000 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	BRN60M	2-[4-[2-(2,6-Dimethylphenoxy)ethyl]piperazin-1-yl]-N-(1,3-thiazol-2-yl)acetamide	Investigative	90643649	C19H26N4O2S	374.5	CC1=C(C(=CC=C1)C)OCCN2CCN(CC2)CC(=O)NC3=NC=CS3	IC50 = 85930 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	BRZ58F	2-[4-(2-Naphthalen-2-yloxyethyl)piperazin-1-yl]-N-(1,3-thiazol-2-yl)acetamide	Investigative	90643653	C21H24N4O2S	396.5	C1CN(CCN1CCOC2=CC3=CC=CC=C3C=C2)CC(=O)NC4=NC=CS4	IC50 = 68030 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	BSEF80	Auglurant	Investigative	60168069	C16H12FN5O2	325.3	CC1=CC(=CC(=N1)C(=O)NC2=NC=C(C=C2)F)OC3=CN=CN=C3	IC50 ~ 100000 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	BV18CO	2-Methyl-1-morpholino-1-phenylpropan-2-ol	Investigative	46885514	C14H21NO2	235.32	CC(C)(C(C1=CC=CC=C1)N2CCOCC2)O	IC50 ~ 60000 nM	Poor binder
T17569	Voltage-gated potassium channel Kv1.5	BVPQ90	N-[3-(N-(6-Fluoro-1,1-dioxo-1,2-benzothiazol-3-yl)anilino)-2,2-dimethylpropyl]piperidine-3-carboxamide	Investigative	52942519	C24H29FN4O3S	472.6	CC(C)(CNC(=O)C1CCCNC1)CN(C2=CC=CC=C2)C3=NS(=O)(=O)C4=C3C=CC(=C4)F	IC50 ~ 50000 nM	Poor binder